Patients with a stable response ( 25 % decrease in Aberrant Behavior Checklist-irritability subscale score and a rating of `` much improved '' or `` very much improved '' on the Clinical Global Impressions-Improvement scale ) for 12 consecutive weeks were randomized into phase 2 to continue aripiprazole or switch to placebo .